Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians.

Auteurs : van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, Seufferlein T
Jaar : 2016
Journal : Cancers (Basel)
Volume : 8

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Auteurs : Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P
Jaar : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(10)
Pagina's : 1792-801

Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.

Auteurs : Gebhart G, Flamen P, de Vries EG, Jhaveri K, Wimana Z
Jaar : 2016
Journal : J Nucl Med
Volume : 57 Suppl 1
Pagina's : 81S-8S

A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.

Auteurs : Lalami Y, Garcia C, Flamen P, Ameye L, Paesmans M, Awada A
Jaar : 2016
Journal : Head Neck
Volume : 38(3)
Pagina's : 347-54

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT.

Auteurs : Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P
Jaar : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(1)
Pagina's : 195-6

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Auteurs : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Jaar : 2016
Journal : Ann Oncol
Volume : 27(4)
Pagina's : 619-24

A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : The QUEST Phantom Study.(103 collaborators : for Institut Bordet : B. Vanderlinden and P. Flamen)

Auteurs : Willowson KP, Tapner M, Bailey DL, + collaborators (among others :, Flamen P, Vanderlinden B
Jaar : 2015
Journal : Eur J Nucl Med Mol Imaging
Volume : 42
Pagina's : 1202-22

Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data.

Auteurs : Paesmans M, Garcia C, Wong CY, Patz EF Jr, Komaki R, Eschmann S, Govindan R, Vansteenkiste J, Meert AP, de Jong WK, Altorki NK, Higashi K, Van Baardwijk A, Borst GR, Ameye L, Lafitte JJ, Berghmans T, Flamen P, Rami-Porta R, Sculier JP
Jaar : 2015
Journal : Eur Respir J
Volume : 46
Pagina's : 1751-61

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.

Auteurs : Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart-Gebhart M, Flamen P
Jaar : 2015
Journal : PLoS One
Volume : 10
Pagina's : e0138341

Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma.

Auteurs : Bouazza F, Poncelet A, Garcia CA, Delatte P, Engelholm JL, Gomez Galdon M, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V
Jaar : 2015
Journal : World J Gastroenterol
Volume : 21
Pagina's : 9666-70

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

Auteurs : Hendlisz A, Deleporte A, Vandeputte C, Charette N, Paesmans M, Guiot T, Garcia C, Flamen P
Jaar : 2015
Journal : BMJ Open
Volume : 5(3)
Pagina's : e007189

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P
Jaar : 2015
Journal : Mol Imaging Biol
Volume : 17(5)
Pagina's : 697-703

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Auteurs : Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D
Jaar : 2015
Journal : Eur J Nucl Med Mol Imaging
Volume : 42(8)
Pagina's : 1304-14

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Auteurs : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart-Gebhart M, Van Laethem JL, Flamen P
Jaar : 2015
Journal : BMC Cancer
Volume : 15
Pagina's : 173

Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance.

Auteurs : Vouche M, Salem R, Miller FH, Lemort M, Vanderlinden B, De Becker D, Hendlisz A, Flamen P
Jaar : 2015
Journal : Clin Imaging
Volume : 39(3)
Pagina's : 454-62

Pooled analysis of the surgical treatment for colorectal cancer liver metastases.

Auteurs : Veereman G, Robays J, Verleye L, Leroy R, Rolfo C, van Cutsem E, Bielen D, Ceelen W, Danse E, De Man M, Demetter P, Flamen P, Hendlisz A, Sinapi I, Vanbeckevoort D, Ysebaert D, Peeters M
Jaar : 2015
Journal : Crit Rev Oncol Hematol
Volume : 94(1)
Pagina's : 122-135

Surgical strategy in abnormally increased Fluorine-18 fluorodeoxyglucose uptake in an asymptomatic lower esophageal submucosal tumor - Report of a case.

Auteurs : Haddad J, Bouazza F, Baraké H, Liberale G, Flamen P, El Nakadi I
Jaar : 2014
Journal : Int J Surg Case Rep
Volume : 5(9)
Pagina's : 589-93

Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres.

Auteurs : Chiesa C, Lambert B, Maccauro M, Ezziddin S, Ahmadzadehfar H, Dieudonné A, Cremonesi M, Konijnenberg M, Lassmann M, Pettinato C, Strigari L, Vanderlinden B, Crippa F, Flamen P, Garin E
Jaar : 2014
Journal : J. Nucl. Med.
Volume : 55(7)
Pagina's : 1215-16

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

Auteurs : Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart-Gebhart M, Flamen P, Hendlisz A
Jaar : 2014
Journal : BMC Cancer
Volume : 14(1)
Pagina's : 385

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Auteurs : Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart-Gebhart M, Vobecky N, Thuresson M, Flamen P
Jaar : 2014
Journal : Breast Cancer Res. Treat.
Volume : 145(2)
Pagina's : 411-8